At a glance
ClinicalIndex Comparison RecordN/ACompleted· 84 enrolled
Drug / intervention
etanercept +1 moredrug
Likely dose
etanercept 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Defining Which Remission Criterion At Month 6 Predicts Remission At Month 12 In A Real Life Clinical Practice, In A Cohort Of Ankylosing Spondylitis Patients Treated With Etanercept (Enbrel (Registered))
In Brief
An observational study evaluating etanercept for Ankylosing Spondylitis. Completed, enrolled 84 participants across 29 sites.
Detailed Summary
Determine which remission criterion at Month 6 predicts remission at Month 12 the best.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAnkylosing Spondylitis
CountriesBelgium
Collaborators--
Timeline
N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedJul 2014
Enrollment StartAug 2014
Primary CompletionApr 2017
TodayJul 2026
First PostedJul 29, 2014
Enrollment StartAug 12, 2014
Primary CompletionApr 26, 2017
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 11.9 years ago
Interventions
etanerceptdrug
etanercept 1 x 50 mg/week or 2 x 25mg/week
etanerceptdrug
etanercept 1 x 50 mg/week or 2 x 25mg/week